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Background: Peri-procedural Creatine Kinase (CKMB) after PCI was repotted to be 
associated with increased mortality. However its impact on patients treated with in-stent 
restenosis (ISR) and intracoronay radiation therapy (IRT) is unknown. Methods: We 
evaluated 1166 patients who were enrolled in radiation trials for ISR using gamma and 
beta emitters. Patients were analyzed according to the degree of CKMB rise within 24 
hours of the index IRT procedure [>4 x baseline, 2-4 x baseline, and <2x baseline (nor- 
mal)]. Results: Patients,with CKMB>4x were older (64 f 12 years, p=O.OOS), had a 
higher rate of multivessel disease (41%, p=O.O44). and were more likely treated with 
excimer laser (36%, p<O.OOl). The cohort with the highest CKMB release (CKMB>4x) 
had significantly higher rates of adverse clinical events at 6 months; including late throm- 
bosis. 
Ron Waksman. Andrew E. Ajani, Lowell F. Satlet, Kenneth M. Kent, Michael Parrazzo. 
Neil J. Weissman, Robert Lew, Rebecca Torguson, Edouard F. Cheneau, Ellen Pinnow, 
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CKMB >4x CKMB 2-4x CKMB <2x (Normal) 
(N=l77) (N=l61) (N=830) P 
In-hospital MACE 11.7 3.4 0.6 <O.OOl 
(Death, Q-Wave MI, TLR). % 
6-month events 
Death, % 4.9 1.4 2.0 0.067 
Q-Wave MI, % 3.7 1.4 0.6 0.004 
TLR, % 20.1 19.4 12.2 0.007 
NR, % 26.6 30.2 16.0 co.oo1 
Late Thrombosis, % 9.8 1.4 1.6 <0.001 
Late Total Occlusion, % 11.0 6.6 3.5 <O.OOl 
MACE, % 22.0 20.1 13.2 0.006 
Conclusions: Post-procedural CKMB elevation is of prognostic impottance in patients 
treated with IRT for ISR. and its analysis appears mandatory to risk stratify these 
patients. 
Background: lntracoroanry radiation (IR) is an effective therapy in preventing recur- 
rences of In-sent restenosis (ISR). However, nearly 20% of the patients (pts) enrolled in 
radiation studies for ISR required repeat revascularization to the irradiated site. Re- 
WRIST ( Washington Radiation for mStent Restenosis Trial) is a registry evaluating the 
safety and efficacy of retreatment with IR in pts with refractory ISR. 
Methods: Twenty-four patients with ISR who had recurrence of stenosis at the previ- 
ously irradiated segment and who failed a subsequent angioplasty were eligible for re- 
treatment with IR if considered a poor surgical candidate. In Re-WRIST the radiation sys- 
tem was a nylon ribbon containing lg21r seeds delivered into a non-centered end lumen 
catheter. The prescribed dose was 15 Gy at 2 mm. The antiplatelet regimen post-proce- 
dure was 6 months of clopidogrel. Patients were followed clinically and anglographically. 
Results: At present, 19 pts have completed 6 months follow-up. The mean age was 65.4 
* 7.7 yrs, 62.5% male, 43.5% diabetic, and 67% had previous CABG. Lesions were in 
native coronary arteries (n=l7), saphenous vein grafts (n=5), and 2 in the left internal 
mammary graft. The mean time intewal between the two radiation treatments is 16.6 * 
7.6 months and the mean number of previous interventions to the target lesion was 4.6 * 
2.7. The utiliziation of devices during the intervention was balloon alone in 10, ex$mer 
laser in 6, atherectomy in 1, and restenting in 7 pts. At 30 days one patient required rein- 
tervention. At 6 months, 5 patients had target lesion revascularnation and none had an 
Ml. Overall. 14 patients are event free. To date, there are no clinlcal or angiographic 
complications (evidence of aneurysm, fibrosis, perforation) in any of the patients. 
Conclusions: Repeat radiation to the same site using ‘% for refractory ISR is safe and 
effective. Complete B-month clinical and angiographic follow-up for the entire cohort will 
be available at presentation. 
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Background: Vascular brachytherapy (VBT) has been shown to be efficacious in the 
treatment of ISR but not denovo (DN) native coronary lesions. The relative effkxcy of 
beta VBT in DN and ISR lesions in SVGsis not known. Methods: In SVG BRITE 49 pts 
with single lesions (25 DN, 24 ISR) in diseaseql SVGs were treated with the Radiance 
RDX P32 balloon (33 mm encapsulated foil source delivering 20 Gy lmm into the vessel 
wall) after successful PCI. Clinical and anglographic FU was obtained at 6 months in all 
pts. QCA included analysis of the radiation edge (RE) fall-off zones and geographic miss 
(GM). Results: Baseline characteristics were well matched, mean lesion length was 13 
mm, and vessel size was 3.31 mm. A new stent was implanted in 60% of DN and 32% of 
ISR lesions. The final MLD (2.7lkO.5 vs. 2.66+0.5. ~~0.7) and %DS (20*9% vs. 22*10, 
p=O.3) were similar. GM for both DN and restenotic pts was infrequent proximally (6.3% 
vs. 4.0%, p=NS) and distally (4.2% vs. O%, p=NS) respectively. There were no deaths, 
Q-wave MIS or stat thromboses. Clinical and angiographic restenosis (RS) rates appear 
in the table. Conclusions Beta VBT with the RDX P32 balloon of both DN and ISR SVG 
lesions results I” low recurnmce rates, especially in DN lesions. Restenosis solely out- 
side the stent cgnfines was uncommon, likely due to infrequent GM. Larger scale evalua- 
tion of this technology in SVGs is warranted. 
Background: Vascular brachytherapy (VBT) reduces the recurrence of in-stent resteno- 
sis (ISR). The optimal radiation dose and the anti-thrombotic regimen remain debated. 
Methods: 240 patients with diffuse ISR in native coronary alteries (lesion length 36-60 
mm) underwent angioplasty and were enrolled in the Washington Radiation for In-Stent 
Restenosis Trial for long lesions (Long WRIST). Of these, 120 patients were randomized 
for either radiation with ‘921r with 15 Gy at 2 mm from the source or placebo. The addi- 
tional 120 patients were treated with ‘921r wth 16 Gy. Of these, the first 60 were treated 
with one month of Anti-Platelet Therapy (APT) while the second 60 patients of the 16 Gy 
group reaeved 6 months of APT. Six months follow-up included angiography and clinical 
outcomes: target lesion revascularization (TLR) and major adverse cardiac events 
(MACE). 
Results: All 240 pts underwent successful IRT therapy. Radiation with 15 Gy reduces 
the recurrence of angiographic restenosis and MACE (Table). A high dose of 16 Gy fur- 
ther reduces restenosis and the event rate. Late thrombosis after VBT was similar to con- 
trol with prolonged APT up to 6 months. Overall, 16 Gy and 6 months of APT resulted in 
66.7% of patinets free of cardiac event at 6 months, as compared to 40% in the placebo 
group. 
Radiation dose, Gy 0 15 16 16 
APTtreatment, months 1 1 1 6 
TLR. % 56.3 30’ 16.3 13.3 
Late thrombosis, % 5 10 6.6 3.3 
MACE, % 60 33.3’ 16.3T 13.3t 
* p<O.O5 15 Gy vs 0 Gy, t p<O.O5 16 Gy vs 15 Gy 
Conclusions: A radiation dose of 18 Gy with prolonged APT optimizes the outcome of 
patients treated for diffuse ISR with’g21r VBT. 
6 month results De Nova Restenotic p Value 
Lesion RS (%) 11.6 30.0 0.24 
stem RS (%) 11.6 25.0 0.41 
Prox Edge RS (%) 16.7 16.6 0.72 
Dist Edge RS (%) 11.6 5.0 0.56 
TLR (%) 4.3 26.1 0.095 
lVR (%) 4.3 26.1 0.095 
